1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21934
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKatsouras, C.en
dc.contributor.authorMichalis, L. K.en
dc.contributor.authorPapamichael, N.en
dc.contributor.authorAdamidis, K.en
dc.contributor.authorNaka, K. K.en
dc.contributor.authorNikas, D.en
dc.contributor.authorGoudevenos, J. A.en
dc.contributor.authorSideris, D. A.en
dc.date.accessioned2015-11-24T19:19:08Z-
dc.date.available2015-11-24T19:19:08Z-
dc.identifier.issn1097-6744-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21934-
dc.rightsDefault Licence-
dc.subjectAcute Diseaseen
dc.subjectAgeden
dc.subjectAngina, Unstable/*drug therapyen
dc.subjectElectrocardiographyen
dc.subjectEnoxaparin/*therapeutic useen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHeparin, Low-Molecular-Weight/*therapeutic useen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMyocardial Infarction/*drug therapy/physiopathologyen
dc.subjectSyndromeen
dc.subjectTime Factorsen
dc.titleEnoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 monthsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1016/j.ahj.2004.09.028-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16169312-
heal.identifier.secondaryhttp://ac.els-cdn.com/S000287030400660X/1-s2.0-S000287030400660X-main.pdf?_tid=686bc90abbcdd9c6af900d54695767ca&acdnat=1337844759_e66cffb4c064b5a6e790ef78db5826be-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractBACKGROUND: We have previously reported significant benefits of using enoxaparin, compared to tinzaparin, in the 7- and 30-day incidence of the composite triple end point of death, myocardial infarction (MI), or recurrent angina in patients with non-ST-segment elevation acute coronary syndromes (NSTACS). In the present study, we aimed to determine whether the observed benefits of enoxaparin were maintained beyond the early phase and report the results of the 6-m follow-up of patients in the EVET study. METHODS: We recruited 438 patients with NSTACS. All patients received oral aspirin and were randomized to also receive enoxaparin, 100 IU/kg subcutaneously twice daily (equivalent to 1 mg/kg twice daily; n = 220), or tinzaparin, 175 IU/kg subcutaneously once daily (n = 218), for up to 7 days. RESULTS: At 6 m, the incidence of the composite triple end point of death, MI, or recurrent angina was lower among patients receiving enoxaparin compared to those receiving tinzaparin (25.5% vs 44.0%, P < .001). A lower incidence of the secondary composite end point of death or MI was also found in the enoxaparin group compared to tinzaparin group (2.7% vs 6.9%, P = .046). The need for revascularization procedures was also lower in the enoxaparin group compared to tinzaparin group (23.2% vs 37.2%, P = .002). CONCLUSIONS: In patients with NSTACS, enoxaparin significantly reduced the rates of recurrent ischemic events and therapeutic procedures in the short term, with sustained benefit at 6 m compared to tinzaparin.en
heal.journalNameAm Heart Jen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Katsouras-2005-Enoxaparin versus ti.pdf237.28 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons